FDA Clears Riverain’s Chest X-ray Software
Riverain Technologies has received FDA 510(k) clearance for software aimed at improving clarity of conventional chest X-rays.
Riverain Technologies has received FDA 510(k) clearance for software aimed at improving clarity of conventional chest X-rays, the company announced.
ClearRead + Confirm also allows radiologists to confirm the proper placement of tubes, lines, and wires, the company said. Portable chest X-ray machines, typically used to confirm line and tube placement, doesn’t have high quality images, and radiologists spend time adjusting the machines to make the edges stand out.
This software increases the readability of the chest X-ray by selectively increasing contrast and suppressing the clavicles and ribs in the image, removing items that could obscure visibility of the lines and tubes.
A Georgetown University reader study assessed the time it took radiologists to locate PICC lines, nasogastric tubes, and wires that conduct or measure electrical impulses. Ten radiologists reviewed 334 X-rays with and without the software, and the software reduced the reading time by 19 percent, according to the company.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
New MRI Study Questions Use of Corticosteroid Injections for Knee OA
May 27th 2025Two years after intraarticular knee injections for knee osteoarthritis (OA), study participants who had corticosteroid knee injections had greater OA progression than control patients while the use of hyaluronic acid injections was associated with less OA progression.
